Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448
- Sponsor
- Yuhan Corporation
- Study ID
- NCT03556436
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 19 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- YH25448 240mg — DRUGperiod 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
Study Details
Clinical trial is to evaluate the effect of ethnicity and food on the pharmacokinetics (how a drug is absorbed, metabolized, distributed and excreted; plasma drug concentration will be measured in this clinical trial) of YH25448, which Yuhan Corporation plans to develop as a therapeutic agent for Non-Small Cell Lung Cancer.
Key Dates
- Start date
- Jul 3, 2018
- Status verified
- Jan 2019
- Primary completion
- Dec 30, 2018
- Completion
- Dec 30, 2018
Study Design
- Enrollment
- 24 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Group 1YH25448 240mg single dose in korean
- Experimental: Group 2YH25448 240mg single dose in caucasian
Primary Outcome Measure
AUClast of YH25448 [ Time Frame: 0-192 hrs ]
Related Studies
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial TumorsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California